Status:

TERMINATED

RapidTEG MA Validation

Lead Sponsor:

Haemonetics Corporation

Conditions:

Coagulation

Platelet Function

Eligibility:

All Genders

18+ years

Brief Summary

During normal physiological conditions hemostasis (the ability of blood to clot) is kept in homeostatic balance by feedback mechanisms. These mechanisms involve an extremely complex series of steps on...

Eligibility Criteria

Inclusion

  • Patient age \> 18 years old
  • Patient is either a Trauma patient OR is diagnosed with known cardiovascular disease.
  • Samples must be tested within the recommended timeline (4-6 minutes for non-citrated and between 15 minutes and 2 hours for citrated)

Exclusion

  • Patients who have been placed on anticoagulation prophylaxis for other conditions (not CPB/PCI related).
  • Patients who have established hemostasis system abnormalities (congenital or other).
  • Samples identified as affected by testing errors by lab staff.

Key Trial Info

Start Date :

July 1 2011

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT01428102

Start Date

July 1 2011

End Date

October 1 2012

Last Update

September 16 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sinai Center for Thrombosis Research

Baltimore, Maryland, United States, 21215

2

Univserity of Tennessee Health Sciences Center

Knoxville, Tennessee, United States, 37996-1529